文献速递消化道肿瘤与早癌消化内镜

全周性cT1aN0M0食管鳞癌ESD长期结局

Long-term outcome after endoscopic submucosal dissection for entire circumferential cT1aN0M0 esophageal squamous cell carcinoma.
PubMed 文献 · Gastrointest Endosc · 2026-01-29

这项回顾性研究比较了全周性cT1aN0M0食管鳞癌患者初始接受ESD、食管切除术或放化疗的长期结局。中位随访95个月,ESD组5年OS/DFS为93%/89%,食管切除组为87%/87%,放化疗组为75%/69%;ESD组食管狭窄/难治性狭窄率高达79%/46%,显著高于其他治疗。

要点

  • 全周性cT1aN0M0食管鳞癌ESD后5年OS/DFS达93%/89%,与食管切除术相当。
  • ESD后食管狭窄率79%、难治性狭窄率46%,明显高于手术和放化疗。
  • ESD治愈性切除率72%,放化疗完全缓解率94%,需大样本明确ESD适应证。

核心结论

  • 全周性cT1aN0M0食管鳞癌各治疗组的长期结局已明确,ESD后食管狭窄和难治性狭窄率高于其他治疗。
  • 需更大规模研究明确此类病变ESD的适应证标准。

研究设计与样本

  • 共59例可评估患者,其中ESD组28例、放化疗组15例、食管切除组16例。
  • 中位随访95个月,评估5年总生存率、5年无病生存率、食管狭窄、难治性狭窄、ESD治愈性切除率及放化疗完全缓解率。

主要发现

  • 5年OS/DFS:ESD组93%/89%,食管切除组87%/87%,放化疗组75%/69%。
  • ESD治愈性切除率为72%。
  • 食管狭窄/难治性狭窄率:ESD组79%/46%,食管切除组20%/13%,放化疗组0%/0%。
  • 放化疗完全缓解率为94%。

关键数值与推荐

  • ESD组5年OS为93%,5年DFS为89%。
  • 食管切除组5年OS为87%,5年DFS为87%。
  • 放化疗组5年OS为75%,5年DFS为69%。
  • ESD治愈性切除率为72%,放化疗完全缓解率为94%。
  • ESD组食管狭窄率79%、难治性狭窄率46%;食管切除组分别为20%、13%;放化疗组均为0%。

临床怎么用

  • 全周性cT1aN0M0食管鳞癌选择ESD时需充分评估狭窄风险,术后狭窄和难治性狭窄发生率高。
  • ESD可作为初始治疗选项之一,但需结合患者意愿和狭窄防治能力个体化决策。
  • 放化疗完全缓解率高,但长期生存低于ESD和手术,需综合权衡。

局限性

  • 回顾性研究,样本量较小(共59例),各组例数有限。
  • 治疗选择基于医师判断,可能存在选择偏倚。
  • 需更大规模队列研究明确ESD适应证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Endoscopic submucosal dissection (ESD) is the standard treatment for cT1a esophageal squamous cell carcinoma (ESCC); however, its indication for the entire circumferential (EC) lesion remains controversial because of the stricture risk after ESD. Therefore, several treatments are administered on the basis of the physician's choice; the clinical course, however, remains unclear. This retrospective study aimed to clarify the long-term outcomes after ESD in patients with circumferential cT1aN0M0 ESCC compared with those after esophagectomy or chemoradiotherapy. METHODS: Patients with circumferential cT1aN0M0 ESCC treated with ESD, chemoradiotherapy, or esophagectomy as the initial treatment between January 2010 and December 2018 were included. The 5-year overall survival (OS), 5-year disease-free survival (DFS), esophageal stricture, refractory stricture, curative ESD resection, and complete response (CR) rates to chemoradiotherapy were evaluated. RESULTS: Of the 59 eligible patients, 28, 15, and 16 patients received ESD, chemoradiotherapy, and esophagectomy, respectively, as the initial treatment. During a median follow-up period of 95 months, the 5-year OS/DFS was 93%/89% after ESD, 87%/87% after esophagectomy, and 75%/69% after chemoradiotherapy. The curative resection rate of ESD was 72%. The esophageal stricture/refractory stricture rates were 79%/46% after ESD, 20%/13% after esophagectomy, and 0%/0% after chemoradiotherapy. The CR rate to chemoradiotherapy was 94%. CONCLUSIONS: The long-term outcomes of each treatment group for EC cT1aN0M0 ESCC were elucidated. The esophageal stricture and refractory stricture rates after ESD were higher than those in other patients. Further investigations in large cohorts are necessary to clarify the indication criteria for ESD in patients with lesions.

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Inaba A, Kadota T, Nishihara K, et al. Long-term outcome after endoscopic submucosal dissection for entire circumferential cT1aN0M0 esophageal squamous cell carcinoma. Gastrointest Endosc. 2026. PMID: 41620142. doi:10.1016/j.gie.2026.01.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。